Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model

被引:62
|
作者
Parrella, Edoardo [1 ,2 ]
Maxim, Tom [1 ,2 ]
Maialetti, Francesca [3 ]
Zhang, Lu [1 ,2 ]
Wan, Junxiang [1 ,2 ]
Wei, Min [1 ,2 ]
Cohen, Pinchas [1 ,2 ]
Fontana, Luigi [4 ,5 ,6 ]
Longo, Valter D. [1 ,2 ]
机构
[1] Univ So Calif, Longev Inst, Davis Sch Gerontol, Los Angeles, CA 90089 USA
[2] Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA
[3] Ist Super Sanita, Div Nutr & Aging, I-00161 Rome, Italy
[4] Washington Univ, Div Geriatr & Nutr Sci, St Louis, MO USA
[5] Univ Salerno, Sch Med, Dept Med, I-84100 Salerno, Italy
[6] CEINGE Biotecnol Avanzate, Naples, Italy
关键词
aging; alzheimer; IGF-1; IGFBP-1; protein restriction; tau; GROWTH-FACTOR-I; AMES DWARF MICE; CALORIC RESTRICTION; NUTRITIONAL REGULATION; TRANSGENIC MODEL; KNOCKOUT MICE; LIFE-SPAN; BRAIN; HORMONE; SERUM;
D O I
10.1111/acel.12049
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In laboratory animals, calorie restriction (CR) protects against aging, oxidative stress, and neurodegenerative pathologies. Reduced levels of growth hormone and IGF-1, which mediate some of the protective effects of CR, can also extend longevity and/or protect against age-related diseases in rodents and humans. However, severely restricted diets are difficult to maintain and are associated with chronically low weight and other major side effects. Here we show that 4months of periodic protein restriction cycles (PRCs) with supplementation of nonessential amino acids in mice already displaying significant cognitive impairment and Alzheimer's disease (AD)-like pathology reduced circulating IGF-1 levels by 3070% and caused an 8-fold increase in IGFBP-1. Whereas PRCs did not affect the levels of amyloid (A), they decreased tau phosphorylation in the hippocampus and alleviated the age-dependent impairment in cognitive performance. These results indicate that periodic protein restriction cycles without CR can promote changes in circulating growth factors and tau phosphorylation associated with protection against age-related neuropathologies.
引用
收藏
页码:257 / 268
页数:12
相关论文
共 50 条
  • [31] Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231
    Hampel, H
    Buerger, K
    Kohnken, R
    Teipel, SJ
    Zinkowski, R
    Moeller, HJ
    Rapoport, SI
    Davies, P
    ANNALS OF NEUROLOGY, 2001, 49 (04) : 545 - 546
  • [32] The Behavioral phenotype of a transgenic mouse model of Alzheimer's disease
    Sood, A
    Buccafusco, JJ
    Terry, AV
    FASEB JOURNAL, 2005, 19 (05): : A1543 - A1543
  • [33] Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies
    Ramakrishnan, P
    Dickson, DW
    Davies, P
    NEUROBIOLOGY OF DISEASE, 2003, 14 (02) : 251 - 264
  • [34] Tau protein phosphorylated at threonine 181 in cerebrospinal fluid as a possible biomarker for Alzheimer's disease
    Verbeek, MM
    Kremer, BP
    Jansen, RW
    de Jong, D
    NEUROBIOLOGY OF AGING, 2004, 25 : S364 - S364
  • [35] Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer's disease
    Kandimalla, Ramesh
    Manczak, Maria
    Yin, Xiangling
    Wang, Rui
    Reddy, P. Hemachandra
    HUMAN MOLECULAR GENETICS, 2018, 27 (01) : 30 - 40
  • [36] Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
    Thijssen, Elisabeth H.
    La Joie, Renaud
    Strom, Amelia
    Fonseca, Corrina
    Iaccarino, Leonardo
    Wolf, Amy
    Spina, Salvatore
    Allen, Isabel E.
    Cobigo, Yann
    Heuer, Hilary
    VandeVrede, Lawren
    Proctor, Nicholas K.
    Lago, Argentina Lario
    Baker, Suzanne
    Sivasankaran, Rajeev
    Kieloch, Agnieszka
    Kinhikar, Arvind
    Yu, Lili
    Valentin, Marie-Anne
    Jeromin, Andreas
    Zetterberg, Henrik
    Hansson, Oskar
    Mattsson-Carlgren, Niklas
    Graham, Danielle
    Blennow, Kaj
    Kramer, Joel H.
    Grinberg, Lea T.
    Seeley, William W.
    Rosen, Howard
    Boeve, Bradley F.
    Miller, Bruce L.
    Teunissen, Charlotte E.
    Rabinovici, Gil D.
    Rojas, Julio C.
    Dage, Jeffrey L.
    Boxer, Adam L.
    LANCET NEUROLOGY, 2021, 20 (09): : 739 - 752
  • [37] DIABETES MELLITUS AGGRAVATES BEHAVIORAL DEFICIT AND INCREASES SITE-SPECIFIC PHOSPHORYLATION OF TAU PROTEIN IN ALZHEIMER'S DISEASE MOUSE MODEL.
    Ito, Yuki
    Takeda, Shuko
    Nakajima, Tsuneo
    Oyama, Akane
    Takeshita, Hikari
    Miki, Kunihiro
    Takami, Yoichi
    Takeya, Yasushi
    Shimamura, Munehisa
    Rakugi, Hiromi
    Morishita, Ryuichi
    JOURNAL OF HYPERTENSION, 2023, 41 : E365 - E365
  • [38] Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer's disease
    Dumont, Magali
    Stack, Cliona
    Elipenhali, Ceyhan
    Calingasan, Noel Y.
    Wille, Elizabeth
    Beal, M. Flint
    NEUROSCIENCE LETTERS, 2011, 492 (03) : 150 - 154
  • [39] Dermatologic diagnosis of neurologic disease: The presence of phosphorylated tau protein in buccal cells of Alzheimer's disease patients
    Saikaly, Sami
    Eng, William
    Fernando Arredondo, Luis
    Aranda-Romo, Saray
    Chi-Ahumada, Erika
    Jimenez-Capdeville, Maria
    Norman, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB94 - AB94
  • [40] Neuronal IGF-1 resistance reduces Aβ accumulation and protects against premature death in a model of Alzheimer's disease
    Freude, Susanna
    Hettich, Moritz M.
    Schumann, Christina
    Stoehr, Oliver
    Koch, Linda
    Koehler, Christoph
    Udelhoven, Michael
    Leeser, Uschi
    Mueller, Marita
    Kubota, Naoto
    Kadowaki, Takashi
    Krone, Wilhelm
    Schroeder, Hannsjoerg
    Bruening, Jens C.
    Schubert, Markus
    FASEB JOURNAL, 2009, 23 (10): : 3315 - 3324